10-K: Vaso Corporation Reports 2.2% Revenue Increase in 2023, Eyes Merger with Achari Ventures

Vaso Corporation's annual report reveals a modest revenue increase and details a planned merger with Achari Ventures Holdings Corp.

Summary

• Vaso Corporation reported a 2.2% increase in total revenues, reaching $81.024 million in 2023, up from $79.294 million in 2022.
• Net income decreased by $6.489 million, from $11.294 million in 2022 to $4.805 million in 2023, primarily due to higher operating expenses and a reduced income tax benefit.
• The company's IT segment saw a slight revenue increase of 0.7%, while the professional sales service segment grew by 3.3%.
• The equipment segment experienced a 10.1% revenue increase, driven by growth in US operations, partially offset by lower sales in China due to foreign exchange fluctuations.
• Gross profit increased by 5.6% to $50.593 million in 2023, compared to $47.902 million in 2022.
• Operating income decreased by 35% to $4.195 million in 2023, down from $6.454 million in 2022, mainly due to higher operating expenses in the professional sales service segment.
• Adjusted EBITDA decreased by $3.330 million to $5.094 million in 2023, from $8.424 million in 2022.
• The company has net operating loss carryforwards of approximately $25 million at December 31, 2023.
• Vaso Corporation has entered into a business combination agreement with Achari Ventures Holdings Corp., expected to close in the second quarter of 2024, valuing Vaso at approximately $176 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is revenue growth, the significant decrease in net income and operating income, along with the risks associated with the GEHC agreement and the business combination, temper the positive aspects. The planned merger is a positive development, but its success is not guaranteed.

Positives

• Total revenues increased by 2.2% year-over-year.
• Gross profit increased by 5.6% year-over-year.
• The equipment segment saw a significant revenue increase of 10.1%.
• The company has a strong cash position with $25.321 million in cash and short-term investments at the end of 2023.
• The company has a business combination agreement in place with Achari Ventures Holdings Corp. which is expected to close in the second quarter of 2024.

Negatives

• Net income decreased by $6.489 million year-over-year.
• Operating income decreased by 35% year-over-year.
• Adjusted EBITDA decreased by $3.330 million year-over-year.
• The IT segment experienced a decrease in NetWolves revenues.
• Operating loss in the equipment segment increased by $271,000.

Risks

• The company's reliance on the GEHC agreement for a significant portion of its revenue and operating income poses a risk if the agreement is terminated.
• The company faces competition in all segments of its business.
• Data security incidents or disruptions in information technology systems could damage the business.
• The company is dependent on key management and technical personnel.
• The company may not receive necessary clearances or approvals from the US FDA or foreign authorities for its medical devices.
• The company has foreign operations and is subject to the associated risks of doing business in foreign countries.
• The company depends on several suppliers for the supply of certain products.
• The company may not have adequate intellectual property protection.
• The company is subject to product liability claims and product recalls.
• The company's common stock is subject to price volatility.
• The company does not intend to pay dividends in the foreseeable future.
• The business combination with Achari is subject to various closing conditions and may not be consummated.
• The dual class structure of the common stock after the business combination will concentrate voting control with the holders of Class B common stock.

Future Outlook

The company expects to generate sufficient cash flow from operations to satisfy its obligations for at least the next twelve months and anticipates the business combination with Achari will close in the second quarter of 2024.

Management Comments

• Management believes that the company's manufacturing capacity and warehouse facility are adequate to meet the current and immediately foreseeable future demand for the production of its medical devices.
• Management expects to continue to expand product and service offerings and market penetration in all business segments.
• Management intends to maintain and improve business performance in the professional sales service segment by increasing market penetration of the GEHC product portfolio.
• Management plans to maintain and grow the equipment business by increasing efficiency and exploring new revenue models.
• Management will continue to seek accretive partnership opportunities and explore options in capital markets for the stock.

Industry Context

The company operates in the healthcare equipment and information technology industries, which are subject to rapid technological changes and regulatory requirements. The company's performance is influenced by factors such as medical insurance reimbursement policies, competitive technology, and economic conditions.

Comparison to Industry Standards

• Vaso's revenue growth of 2.2% is modest compared to some high-growth tech companies in the healthcare IT sector, but it is a positive sign in a competitive market.
• The decrease in net income and operating income is a concern, and the company will need to improve its cost management and operational efficiency to achieve better profitability.
• The company's reliance on the GEHC agreement is a significant risk, similar to other companies that rely heavily on a single major customer or partner.
• The planned merger with Achari is a strategic move that could provide Vaso with access to capital and a national securities market listing, which could improve its competitive position.
• The company's adjusted EBITDA of $5.094 million is relatively low compared to some of its competitors in the medical device and healthcare IT sectors, indicating a need for improved profitability.

Related Party Transactions

• David Lieberman, Vice Chairman of the Board, is of counsel to the law firm of Ortoli Rosenstadt, LLP, which performs certain legal services for the Company and its subsidiaries.

Stakeholder Impact

• Shareholders will be impacted by the planned merger with Achari Ventures Holdings Corp.
• Employees may be affected by changes in the company's structure and operations.
• Customers will continue to receive products and services from the company.
• Suppliers will continue to provide parts and components to the company.
• Creditors will be impacted by the company's financial performance and the planned merger.

Next Steps

• The company will continue to focus on expanding its product and service offerings.
• The company will work towards completing the business combination with Achari Ventures Holdings Corp.
• The company will continue to monitor and assess its compliance with regulations.
• The company will continue to explore options in capital markets for its stock.

Key Dates

Keywords

Vaso Corporation, Achari Ventures, Merger, Healthcare IT, Medical Devices, GE HealthCare, Revenue, Net Income, EBITDA, Financial Results, Business Combination, Managed Network Services, Diagnostic Imaging, EECP Therapy, Ambulatory Monitoring